International uniform response criteria for multiple myeloma

The methods to consider when analyzing the outcomes of myeloma clinical trials have been expanded in the European Group for Blood and Bone Marrow Transplant/ International Bone Marrow Transplant Registry. This revised form of International Response Criteria may possibly be widely used in future clinical trials. Some of these improvements and expansions are the following:

  • added categories for stringent complete response and very good partial response
  • added serum free light-chain assay to evaluate patients
  • clarified inconsistencies from prior methods of response
  • highlighted importance on time to event and response duration as critical end points.



BGM Durie, J-L Harousseau, JS Miguel, J Blade, B Barlogie, K Anderson, M Gertz, M Dimopoulos, J Westin, P Sonneveld, H Ludwig, G Gahrton, M Beksac, J Crowley, A Belch, M Boccadaro, I Turesson, D Joshua, D Vesole, R Kyle, R Alexanian, G Tricot, M Attal, G Merlini, R Powles, P Richardson, K Shimizu, P Tosi, G Morgan and SV Rajkumar on behalf of the International Myeloma Working Group

Learn more at:

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.